Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Non-Current Debt (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Non-Current Debt for 17 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 58.98% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 58.98% year-over-year, with the annual reading at $1.7 billion for FY2025, 58.98% up from the prior year.
  • Non-Current Debt hit $1.7 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.7 billion in Q4 2025 to a low of $733.1 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $1.0 billion across 5 years, with a median of $837.8 million in 2023.
  • Biggest five-year swings in Non-Current Debt: decreased 18.28% in 2021 and later surged 58.98% in 2025.
  • Year by year, Non-Current Debt stood at $824.3 million in 2021, then decreased by 11.05% to $733.1 million in 2022, then increased by 12.61% to $825.6 million in 2023, then surged by 31.78% to $1.1 billion in 2024, then surged by 58.98% to $1.7 billion in 2025.
  • Business Quant data shows Non-Current Debt for IART at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.1 billion in Q2 2025.